RT Journal Article
SR Electronic
T1 Immunogenicity and safety of fractional doses of yellow fever vaccines: a randomized, double-blind, non-inferiority trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.18.20177527
DO 10.1101/2020.08.18.20177527
A1 Aitana Juan-Giner
A1 Derick Kimathi
A1 Kyra H. Grantz
A1 Mainga M. Hamaluba
A1 Patrick Kazooba
A1 Patricia Njuguna
A1 Gamou Fall
A1 Moussa Dia
A1 Ndeye S. Bob
A1 Thomas P. Monath
A1 Alan D. Barrett
A1 Joachim Hombach
A1 Edgar M. Mulogo
A1 Immaculate Ampeire
A1 Henry K. Karanja
A1 Dan Nyehangane
A1 Juliet Mwanga-Amumpaire
A1 Derek A.T. Cummings
A1 Philip Bejon
A1 George M. Warimwe
A1 Rebecca F. Grais
YR 2020
UL http://medrxiv.org/content/early/2020/10/29/2020.08.18.20177527.abstract
AB Background Yellow fever vaccine stocks have been insufficient to cover exceptional demands for outbreak response. Fractional dosing evidence is limited to the 17DD substrain vaccine. We assessed the immunogenicity and safety of one-fifth fractional dose compared to standard dose of each of the four WHO-prequalified yellow fever vaccines produced from three substrains.Methods We conducted a randomized, double-blind, non-inferiority trial in Mbarara, Uganda and Kilifi, Kenya. 960 participants aged 18-59 years without history of yellow fever vaccination or infection were recruited from communities and randomized to a vaccine and dosage. Vaccine was administered subcutaneously by unblinded nurse. Other study personnel and participants were blinded to vaccine allocation. Primary immunogenicity outcome, seroconversion, was measured in the per-protocol population; safety outcomes included all vaccinated participants. We defined non-inferiority as less than 10% decrease in seroconversion in fractional compared to standard dose arms 28 days post-vaccination. Seroconversion was ≥4-fold rise in neutralizing antibody titers measured by 50% plaque reduction neutralization test.ClinicalTrials.gov Identifier: NCT02991495, completed.Findings Between 6th November 2017 and 21st February 2018, 960 participants, total sample goal, were randomized. The primary per-protocol analysis includes 899 participants, 110 to 117 participants per arm. The absolute difference in seroconversion between fractional and standard doses by vaccine was 1.71% (95%CI: −2.60, 5.28) for Bio-Manguinhos, −0.90% (95%CI: −4.24, 3.13) for Chumakov Institute, 1.82% (95%CI: −2.75, 5.39) for Institut Pasteur de Dakar, 0.0% (95%CI: −3.32, 3.29) for Sanofi Pasteur. Fractional doses from all four vaccines met the non-inferiority criterion. The most common related AEs were headache (22.2%), fatigue (13.7%), myalgia (13.3%) and self-reported fever (9.0%). There were no safety concerns.Interpretation These results support fractional dosing of all WHO-prequalified yellow fever vaccines for the general adult population for outbreak response in situations of vaccine shortage.Funding The study was funded by Médecins Sans Frontières Foundation, Wellcome Trust (grant no. 092654) and the UK Department for International Development. Vaccines were donated in kind.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT02991495Funding StatementThe study was funded by Mé;decins Sans Frontières Foundation, Wellcome Trust (grant no. 092654) and the UK Department for International Development. Vaccines were donated in kind.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the ethics committee of the World Health Organization (Switzerland); Scientific & Ethics Review Unit, Kenya Medical Research Institute (Kenya); Oxford Tropical Research Ethics Committee (United Kingdom); Mbarara University of Science and Technology Research Ethics Committee (Uganda); and the Uganda National Council of Sciences and Technology (Uganda). Approval was obtained from the national regulatory authorities in Uganda and Kenya. The trial was conducted in accordance with Good Clinical Practice guidelines.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAnalytic code and a deidentified dataset are available upon request to dpco@epicentre.msf.org.